Transcatheter Aortic Valve Replacement 2016
Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in pat...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Vahl, Torsten P. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
16 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Bimetallic diffusion modeling and temperature regulation during ball milling - Aureli, Matteo ELSEVIER, 2018, JACC, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:67 ; year:2016 ; number:12 ; day:29 ; month:03 ; pages:1472-1487 ; extent:16 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jacc.2015.12.059 |
|---|
| Katalog-ID: |
ELV019438370 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV019438370 | ||
| 003 | DE-627 | ||
| 005 | 20230625125955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2015.12.059 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016013000028.pica |
| 035 | |a (DE-627)ELV019438370 | ||
| 035 | |a (ELSEVIER)S0735-1097(16)00321-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Vahl, Torsten P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcatheter Aortic Valve Replacement 2016 |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 16 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. | ||
| 520 | |a Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. | ||
| 650 | 7 | |a coronary artery disease |2 Elsevier | |
| 650 | 7 | |a aortic stenosis |2 Elsevier | |
| 650 | 7 | |a mitral valve |2 Elsevier | |
| 650 | 7 | |a transcatheter heart valve |2 Elsevier | |
| 650 | 7 | |a heart valve diseases |2 Elsevier | |
| 700 | 1 | |a Kodali, Susheel K. |4 oth | |
| 700 | 1 | |a Leon, Martin B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Aureli, Matteo ELSEVIER |t Bimetallic diffusion modeling and temperature regulation during ball milling |d 2018 |d JACC |g New York, NY |w (DE-627)ELV000161896 |
| 773 | 1 | 8 | |g volume:67 |g year:2016 |g number:12 |g day:29 |g month:03 |g pages:1472-1487 |g extent:16 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jacc.2015.12.059 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 67 |j 2016 |e 12 |b 29 |c 0329 |h 1472-1487 |g 16 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t p v tp tpv |
|---|---|
| matchkey_str |
vahltorstenpkodalisusheelkleonmartinb:2016----:rncteearivlee |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2016 |
| allfields |
10.1016/j.jacc.2015.12.059 doi GBVA2016013000028.pica (DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Vahl, Torsten P. verfasserin aut Transcatheter Aortic Valve Replacement 2016 2016transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier Kodali, Susheel K. oth Leon, Martin B. oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 https://doi.org/10.1016/j.jacc.2015.12.059 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 67 2016 12 29 0329 1472-1487 16 045F 610 |
| spelling |
10.1016/j.jacc.2015.12.059 doi GBVA2016013000028.pica (DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Vahl, Torsten P. verfasserin aut Transcatheter Aortic Valve Replacement 2016 2016transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier Kodali, Susheel K. oth Leon, Martin B. oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 https://doi.org/10.1016/j.jacc.2015.12.059 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 67 2016 12 29 0329 1472-1487 16 045F 610 |
| allfields_unstemmed |
10.1016/j.jacc.2015.12.059 doi GBVA2016013000028.pica (DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Vahl, Torsten P. verfasserin aut Transcatheter Aortic Valve Replacement 2016 2016transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier Kodali, Susheel K. oth Leon, Martin B. oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 https://doi.org/10.1016/j.jacc.2015.12.059 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 67 2016 12 29 0329 1472-1487 16 045F 610 |
| allfieldsGer |
10.1016/j.jacc.2015.12.059 doi GBVA2016013000028.pica (DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Vahl, Torsten P. verfasserin aut Transcatheter Aortic Valve Replacement 2016 2016transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier Kodali, Susheel K. oth Leon, Martin B. oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 https://doi.org/10.1016/j.jacc.2015.12.059 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 67 2016 12 29 0329 1472-1487 16 045F 610 |
| allfieldsSound |
10.1016/j.jacc.2015.12.059 doi GBVA2016013000028.pica (DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Vahl, Torsten P. verfasserin aut Transcatheter Aortic Valve Replacement 2016 2016transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier Kodali, Susheel K. oth Leon, Martin B. oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 https://doi.org/10.1016/j.jacc.2015.12.059 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 67 2016 12 29 0329 1472-1487 16 045F 610 |
| language |
English |
| source |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 |
| sourceStr |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:67 year:2016 number:12 day:29 month:03 pages:1472-1487 extent:16 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
coronary artery disease aortic stenosis mitral valve transcatheter heart valve heart valve diseases |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| authorswithroles_txt_mv |
Vahl, Torsten P. @@aut@@ Kodali, Susheel K. @@oth@@ Leon, Martin B. @@oth@@ |
| publishDateDaySort_date |
2016-01-29T00:00:00Z |
| hierarchy_top_id |
ELV000161896 |
| dewey-sort |
3610 |
| id |
ELV019438370 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019438370</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625125955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2015.12.059</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016013000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019438370</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(16)00321-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vahl, Torsten P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transcatheter Aortic Valve Replacement 2016</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">coronary artery disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aortic stenosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mitral valve</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">transcatheter heart valve</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart valve diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kodali, Susheel K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leon, Martin B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:12</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:1472-1487</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2015.12.059</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2016</subfield><subfield code="e">12</subfield><subfield code="b">29</subfield><subfield code="c">0329</subfield><subfield code="h">1472-1487</subfield><subfield code="g">16</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Vahl, Torsten P. |
| spellingShingle |
Vahl, Torsten P. ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Transcatheter Aortic Valve Replacement 2016 |
| authorStr |
Vahl, Torsten P. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000161896 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl Transcatheter Aortic Valve Replacement 2016 coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases Elsevier |
| topic |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases |
| topic_unstemmed |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases |
| topic_browse |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier aortic stenosis Elsevier mitral valve Elsevier transcatheter heart valve Elsevier heart valve diseases |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s k k sk skk m b l mb mbl |
| hierarchy_parent_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| hierarchy_parent_id |
ELV000161896 |
| dewey-tens |
610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000161896 |
| title |
Transcatheter Aortic Valve Replacement 2016 |
| ctrlnum |
(DE-627)ELV019438370 (ELSEVIER)S0735-1097(16)00321-1 |
| title_full |
Transcatheter Aortic Valve Replacement 2016 |
| author_sort |
Vahl, Torsten P. |
| journal |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| journalStr |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
1472 |
| author_browse |
Vahl, Torsten P. |
| container_volume |
67 |
| physical |
16 |
| class |
610 610 DE-600 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Vahl, Torsten P. |
| doi_str_mv |
10.1016/j.jacc.2015.12.059 |
| dewey-full |
610 600 690 |
| title_sort |
transcatheter aortic valve replacement 2016 |
| title_auth |
Transcatheter Aortic Valve Replacement 2016 |
| abstract |
Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. |
| abstractGer |
Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. |
| abstract_unstemmed |
Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
12 |
| title_short |
Transcatheter Aortic Valve Replacement 2016 |
| url |
https://doi.org/10.1016/j.jacc.2015.12.059 |
| remote_bool |
true |
| author2 |
Kodali, Susheel K. Leon, Martin B. |
| author2Str |
Kodali, Susheel K. Leon, Martin B. |
| ppnlink |
ELV000161896 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.jacc.2015.12.059 |
| up_date |
2024-07-06T21:27:05.540Z |
| _version_ |
1803866577873928192 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019438370</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625125955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2015.12.059</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016013000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019438370</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(16)00321-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vahl, Torsten P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transcatheter Aortic Valve Replacement 2016</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Transcatheter aortic valve replacement (TAVR) has become a safe and effective therapy for patients with severe aortic stenosis (AS). In recent trials, the hemodynamic performance and clinical outcomes of the latest generation of TAVR devices demonstrated at least parity with surgical outcomes in patients of similar risk. Many initial obstacles with TAVR have largely been overcome, including frequent access site complications and concerns about strokes and paravalvular leaks. Using a multidisciplinary heart team approach, patient selection, procedural planning, and device implantation have been refined and optimized such that clinical outcomes are generally predictable and reproducible. Future research will focus on the durability of TAVR devices, further enhancements in clinical outcomes, and adjunctive therapies. On the basis of initial results from ongoing clinical trials, the indication for TAVR will likely expand to lower-risk patients. This review provides an overview of recent progress in this field, and highlights future opportunities and directions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">coronary artery disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aortic stenosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mitral valve</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">transcatheter heart valve</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart valve diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kodali, Susheel K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leon, Martin B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:12</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:1472-1487</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2015.12.059</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2016</subfield><subfield code="e">12</subfield><subfield code="b">29</subfield><subfield code="c">0329</subfield><subfield code="h">1472-1487</subfield><subfield code="g">16</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400729 |